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Abstract: Paired box 4 (PAX4) is a key factor in the generation of insulin producing β-cells during
embryonic development. In adult islets, PAX4 expression is sequestered to a subset of β-cells that
are prone to proliferation and more resistant to stress-induced apoptosis. The importance of this
transcription factor for adequate pancreatic islets functionality has been manifested by the association
of mutations in PAX4 with the development of diabetes, independently of its etiology. Overexpression
of this factor in adult islets stimulates β-cell proliferation and increases their resistance to apoptosis.
Additionally, in an experimental model of autoimmune diabetes, a novel immunomodulatory
function for this factor has been suggested. Altogether these data pinpoint at PAX4 as an important
target for novel regenerative therapies for diabetes treatment, aiming at the preservation of the
remaining β-cells in parallel to the stimulation of their proliferation to replenish the β-cell mass
lost during the progression of the disease. However, the adequate development of such therapies
requires the knowledge of the molecular mechanisms controlling the expression of PAX4 as well as
the downstream effectors that could account for PAX4 action.
Keywords: PAX4; transcription regulation; SUMOylation; diabetes mellitus; β-cell adaptation;
regenerative therapy
1. Introduction
Diabetes Mellitus (DM) is a metabolic disease characterized by hyperglycemia due to defects in
insulin secretion by pancreatic β-cells, insulin action on target tissues or a combination of both [1].
Due to the dramatic rise in DM incidence in the last decades, this disease has become a leading health
problem worldwide; according to the International Diabetes Federation (www.idf.org), the number of
people affected by DM is expected to increment from current estimates of 415 million to 642 million by
the year 2040. This escalation in DM cases is mainly due to the increase of Type 2 Diabetes Mellitus
(T2DM) that nowadays accounts for as much as 90% of all diabetes cases. The main underlying reason
is the increased prevalence of obesity in our society. Nevertheless, although overweight is a major
factor contributing to T2DM, only 20%–40% of obese individuals develop T2DM [2]. This fact, together
with the existence of family history of DM in type 2 diabetic patients indicates that T2DM has a
strong genetic component. Interestingly, the majority of the identified T2DM susceptibility genes are
related to β-cell function, indicating that alterations in the performance of β-cells which are unable to
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compensate for the increased insulin demand in obese individuals, is the main triggering factor of the
disease. However, these susceptibility loci only explain 10%–20% of T2DM heritability [3–5]. One of
the possible reasons is the polygenic nature of T2DM, caused by the interplay between different genetic
variants and environmental factors. Therefore, single polymorphisms with minor impact would
be associated with T2DM only when several of them are combined and genetic and environmental
interactions are taken into account [6,7]. This fact could explain, at least in part, the apparent ethnic
specificity of some of T2DM susceptibility genes, such as with the Paired box 4 (PAX4). Two single
nucleotide polymorphisms (SNPs), rs6467136 and rs10229583, in intergenic regions close to PAX4 have
been associated with T2DM by genome-wide association studies (GWAS) in Asian populations [8,9].
Moreover, mutations in PAX4 have been associated, not only with the development of T2DM and
with one of the Maturity-Onset Diabetes of the Young (MODY) subtypes, MODY9 in East Asian
families [10,11], but also with ketosis prone diabetes in individuals of West African origin and with
Type 1 Diabetes Mellitus (T1DM) in some European populations. Therefore, PAX4 is one of the
few genes whose polymorphisms/mutations have been associated with several forms of DM [10].
Altogether, this data pinpoints at PAX4 as a key DM susceptibility gene, marking it as a valuable
target for the development of new therapies for DM treatment independently of the disease etiology.
Harnessing the genetic, epigenetic and posttranslational mechanisms regulating PAX4 levels/activity
is mandatory for the adequate development of novel approaches for DM treatment.
2. PAX4 in Islet Physiology: Key Player in β-Cell Generation, Survival and Proliferation
PAX4 belongs to the Pax gene family, a group of evolutionary conserved transcription factors
involved in embryonic organogenesis as well as in cell plasticity in the adult [12–16]. PAX4 is mainly
expressed in the endocrine pancreas where it plays an essential role in the generation of insulin
producing β-cells during embryonic development and later on, during adulthood, is a β-cell master
regulator in adaptation processes [10,17–19].
2.1. PAX4 Essential Role for β-Cell Generation during Embryogenesis
During pancreas development PAX4 is initially expressed in all endocrine progenitors [20,21],
being thereafter implicated in the commitment of β/δ progenitors and further development of
β-cells [22,23]. The lack of this gene in mouse models leads to the near absence of β- and δ-cells,
coupled to an increase in the number of α-cells, rendering the animals severely hyperglycemic leading
to neonatal death [22–24]. Further evidence on PAX4 triggering β-cell commitment arises from
transgenic mouse models where induction of PAX4 expression in early pancreatic epithelium, or in
endocrine committed precursor cells induces the formation of insulin producing β-cells at the expense
of all other islet cell phenotypes [25]. In agreement with this, ectopic expression of PAX4 potentiates
the in vitro generation of insulin+ β-like cells [26–32].
2.2. PAX4 Implications in Adult Islet Plasticity
In adult pancreatic islets, PAX4 is implicated in β-cell plasticity as evidenced by both
in vitro and in vivo studies. Treatments of β-cell lines and rodent islets with mitogens (such
as activin A or betacellulin) or with high glucose increase both PAX4 expression and β-cell
proliferation [33,34]. Moreover, ectopic expression of mouse PAX4 in human or rat adult islets
enhances β-cell proliferation [33]. Strikingly, human PAX4, in contrast to its mouse counterpart,
does not induce proliferation in isolated islets [34]. Besides this pro-proliferative role, PAX4 expression
has also been linked to increased β-cell survival. Induction of endogenous PAX4 levels or ectopic
expression of this factor have been associated with increased expression of anti-apoptotic members of
the intrinsic apoptotic pathway, correlating with improved survival of β-cells and higher resistance to
cytokine-induced apoptosis [33,35–37]. Silencing PAX4 in insulinoma cell lines decreases the expression
of anti-apoptotic factors concomitantly with the increase in spontaneous apoptosis as well as with
higher sensitivity to cytokine-induced cell death [38]. The pro-proliferative and anti-apoptotic role of
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PAX4 has been validated in vivo in a mouse model that conditionally over-express PAX4 specifically
in β-cells. Over-expression of PAX4 in vivo protects β-cells from apoptosis induced by streptozotocin
(STZ) and in a mouse model of experimental autoimmune diabetes (RIPB7.1 mice) [37,39]. Remarkably,
in the latter model, PAX4 overexpression decreases islet immune cell infiltration (insulitis), suggesting
a novel immunomodulatory function of PAX4 [39].
Interestingly, long term ectopic expression of PAX4 in vivo increases proliferation of PDX1+
β-cells that express low to undetectable levels of insulin [37]. This increase in β-cell proliferation
results in blunted glucose stimulated insulin secretion (GSIS) correlating with altered islet morphology,
effects that are reversed upon inhibition of PAX4 expression. These data suggest a PAX4-mediated
dedifferentiation of mature β-cells to allow their proliferation. In agreement with this, in islet β-cell
tumors induced by the loss of Menin1 (Men1), lesions become progressively INS− concomitantly with
the increase in activin B and PAX4 levels [40]. Likely activin B mediated activation of Pax4 expression
contributes to the dedifferentiation of β-cells observed during progression of Men1-/- tumors [40].
The correlation of sustained PAX4 expression with dedifferentiation of β-cells may seem contradictory
with the fact that PAX4 is expressed in β-cells of adult islets. Possibly, a threshold level of PAX4
is required to trigger PAX4 dedifferentiation potential. Moreover, the well-known heterogeneity
among islet β-cells is also evidenced in PAX4 expression. A recent report from our group has shown
that, in adult mouse islets, PAX4 expression is only detected in a subpopulation of β-cells that are
prone to proliferation and more resistant to apoptosis. Furthermore, the relative abundance of this
subpopulation of PAX4+β-cells correlates with the proliferative capacity of the islets [21], leading us
to speculate that this subpopulation of PAX4+β-cells is responsible for β-cell plasticity in response to
external stimuli in vivo.
Besides the important role of PAX4 on β-cells, experimental ectopic PAX4 expression in α-cells
in vivo induces their transdifferentiation into functional β-like cells independently of mice age [25,41].
This PAX4-mediated transdifferentiation of α-cells has also been proven in vitro after adenoviral
overexpression of PAX4 in the α-TC cell line [42]. Moreover, intraperitoneal injection of these
transdifferentiated β-like cells into hyperglycemic mice results in transient improvement of the
glycemic levels [42]. The possibility of transdifferentiating α-cells into functional β-like cells by
the overexpression of a single transcription factor reinforces the concept of PAX4 as a β cell master
regulator. However, in agreement with the required decrease of PAX4 levels to allow final maturation
of β-cells, transdifferentiated monohormonal insulin+ cells express lower levels of PAX4 as compared
to bihormonal intermediate glucagon+/insulin+ cells [42].
Altogether, these data indicate that PAX4 plays a crucial role in β-cell commitment during
development, in the maintenance of more responsive adult β-cell able to adapt to environmental
challenges as well as in the transdifferentiation of α-cells into functional β-cells. This pinpoints at
PAX4 as an important target for the development of novel therapies aiming at the regeneration of the
β-cell mass lost during the progression of DM. Thus, understanding the genetics of PAX4 regulation as
well as identification of its downstream target genes is a priority.
3. PAX4 Molecular Structure and Mechanism of Action
PAX4, as well as other members of the Pax family, are sequence specific transcription factors
that exert their action through binding to defined cis-acting sequences located in both promoters
and enhancers of target genes [43]. In mammals, Pax family is comprised of nine members (PAX1
to PAX9) divided into four groups based on the organization of three conserved structural motifs:
the highly conserved 127–128 amino acid DNA binding paired domain (PD) common to all family
members, a complete or truncated DNA interacting homeodomain (HD), and the octapeptide (OP)
motif located between the PD and the HD (Figure 1A). PAX4, together with PAX6, constitute group
IV of the Pax family, characterized by the presence of the PD and a complete HD, but lacking the
OP [44]. PAX4 and PAX6 are highly homologous in the PD and HD (70% and 65%, respectively),
with no obvious homology outside these domains [44] (Figure 1B).
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Figure 1. PAX4 DNA binding domains share high homology with PAX6. (A) Schematic representation
of Pax family members and their division into four groups based on their structural domains: paired
domain (PD), octapetide (OP) and homeodomain (HD). (B) Alignment of mouse PAX4 (UniProtKB
P32115) and mouse PAX6 (UniProtKB P63015) protein sequences using Clustal Omega Analysis Tool
Web Services from the EMBL-EBI. Conservation code: {*} fully conserved residue {:} conservation
between groups of strongly similar properties and {.} conservation between groups of weakly similar
properties. (C) Schematic representation of full length PAX4 protein identified in islets and the truncated
variants foun i insulinoma samples. Color code: PD is i dicated in purple, HD in blue and OP
in yellow. Black indicates mutation caused new sequence unrelated to PAX4. Green box indicates
the region where the transactivation domain (TAD) is located and red box the region including the
repressor domain.
The presence of two DNA binding domains (DBDs) in these transcription factors confers a high
complexity in their DNA sequence recognition. The N-terminal PD, comprising the main DBD, is on
its own a complex bipartite structure composed of two helix-turn-helix (HTH) motifs separated by a
flexibl c served polypeptid chain. The N-terminal subdomain, ter ed PAI, is a highly co served
region that confers DNA sequence recognition. The C-terminal subdomain, the RED subdomain,
is more divergent and, despite presenting lower affinity for DNA in some PAX proteins, can modify the
binding specificity of the PD [45–49]. The flexible linker between these two HTH motifs also establishes
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contact with DNA [47]. The second DBD, the HD, can also bind independently and with high affinity to
specific DNA sequences; nevertheless, a cooperative action of the PD and the HD on DNA recognition
has been documented [50], and functional interdependence between these two domains regulates PAX
proteins binding to their target gene regulatory elements [48,51–53]. This double DBD with possibility
of independent vs. cooperative action confers extraordinary flexibility of sequence recognition to
each PAX protein hindering the correct prediction of recognition sites by sequence analysis of the
putative target genes. Nonetheless, analysis of PAX4 binding sites using either the isolated PAX4
PD [54] or a truncated form of PAX4 that contains both DBDs [44], determined that PAX4 PD binding
site has a seven-nucleotide core similar to the consensus motifs identified for other PAX proteins.
Nevertheless, it is important to note that in these two studies some differences in the identified
consensus sequence were observed. While in the study using only the PD the recognized sequence
is (G/T)T(C/G)A(T/A)GC, the identified consensus motif for the PD when both DBDs are present
in the same protein is ANNN(C/T)CACCC. One can speculate that these differences can be due to
the presence or not of the HD that can modify the binding characteristics of the PD. The binding site
for PAX4 HD itself contains the consensus TAAT motif characteristic for HD containing factors [44].
Nevertheless, due to limitations of the approach used, the existence of other important sites for
specificity of the binding cannot be excluded.
Because of the high conservation between PAX4 and PAX6 DBDs, the consensus binding site for
PAX4 is similar, but not identical, to the consensus for PAX6. This similarity can explain the capacity
of PAX4 PD as well as the full length protein to bind to PAX6 sites, however with less affinity than
PAX6, allowing competition of both factors for the same targets [44,54,55]. However, the lower affinity
of PAX4 for these binding sites together with its lower expression in pancreatic β-cells as compared
to PAX6 also suggest that these two factors have different and specific target genes. The functional
importance of PAX4 DBDs is clearly established by the fact that the majority of PAX4 mutations
associated with diabetes are located within these domains [10,11]. One of the best characterized
diabetes-linked mutations of PAX4 is R121W (homolog to R129W in mouse). This single amino acid
substitution in the PD of PAX4 alters the DNA binding capacity of the factor [33,56], leading to an
impaired protection of β-cells against apoptosis [37].
In addition to its DNA binding properties, the PD can also engage in protein–protein interactions
that modulate the transcriptional activity of the factor. Both PAX3 and PAX6 interact with members of
the Sox family, resulting in synergistic transcription activation of specific target genes [57,58]. The PD
of PAX6 is needed for this interaction [57]. Moreover, PAX4 and PAX6 also interact via the PD of PAX6.
The region of PAX4 involved in this binding has not yet been characterized [55]. Based on the sequence
homology between the PDs of PAX4 and PAX6, it can be anticipated that PAX4 PD is also involved in
protein–protein interactions; however, putative partners of PAX4 remain uncharacterized. In addition,
the PD can also act as a protein transduction domain (PTD). PAX4 intact PD, as well as PAX6 and PAX5
PDs allow protein transduction into living cells. Incubation of different cell lines as well as isolated rat
islets with recombinant PAX4 protein results in the entrance of functional PAX4 protein into cells [35].
The PTDs are normally highly basic peptides, however PAX4 PD has a low content of basic amino
acids. This fact together with the requirement of an intact PD suggests that the conserved 3D structure
of PAX proteins PD is determinant for efficient transduction.
The C-terminal region of PAX proteins is the more divergent part among the different members
of the family. This region is rich in Proline/Serine/Threonine and contains a transactivation domain
(TAD). Precise localization of these TADs requires further characterization [49,59]. In some members,
as in PAX6, the TAD activity seems to be independent of cell type [43]. However, the activity of the
PAX4 TAD (located in a region between amino acids 232 to 314 of mouse PAX4) (Figure 1C) is cell-type
dependent, and often associated with E1A-like activity, a marker of undifferentiated cell status [54].
One unique characteristic of PAX4 is the presence of a negative regulatory domain (within the amino
acids 274 to 349 of mouse PAX4) juxtaposed to the TAD (Figure 1C). This domain confers a transcription
repressor function to PAX4 that can hinder the activity of other TADs in fused proteins [54]. This
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repressor domain is active regardless of cell type, suggesting that it interacts with a ubiquitous
co-repressor or exerts its action directly through interaction with the transcription machinery [54].
Interestingly, insulinomas express truncated variants of PAX4 characterized by modified C-terminal
domains with functional PD and HD [60–63] (Figure 1C). In vitro functional analysis of such a variant
revealed that this truncated protein binds DNA as efficiently as the wild type (WT) protein, but
activates rather than repress gene transcription [63]. Although further studies are required to elucidate
the physiological role of PAX4 in insulinomas, it is tempting to speculate that this transcription activator
role of truncated PAX4 may be one of the underlying reasons of the uncontrolled cell proliferation.
In addition to this repressor domain in the C-terminal end of PAX4 protein, the existence of a second
repressor domain located between amino acids 2 and 230 has also been suggested, however the precise
location of this domain has not yet been characterized [54,62].
4. PAX4 Mechanism of Action: Downstream Regulated Genes
Since in islet β-cells PAX4 and PAX6 are co-expressed and PAX4 can bind to the same binding sites
as PAX6, the interaction between these two factors will determine the regulatory outcome of different
target genes [10]. The functional relevance of this interaction was analyzed in reporter assays using
PAX6 consensus sites upstream of a minimal promoter. Increasing concentration of PAX4 competed
with PAX6 for binding, resulting in decreased reporter expression [44,54]. This decrease is the result of
two different processes, the blocking of PAX6-dependent activation and the inhibitory action of PAX4
repressor domain [54].
In an attempt to elucidate the molecular mechanisms underlying PAX4 action on β-cell phenotype
the effect of PAX4 on key islet cells genes has been studied. Analysis of the effect of PAX4 onto
different islet hormones expression has revealed that PAX4 inhibits the expression of glucagon,
ghrelin and insulin. Ectopic expression of PAX4 in α-cell lines results in inhibition of glucagon
gene expression [55,64]. This action is mediated, at least in part, by specific competition with PAX6
for the binding to G1 and/or G3 elements of the glucagon gene promoter [55]. Interestingly, human
PAX4 has less affinity than mouse PAX4 for this glucagon G3 element [34]. This DNA binding
differences between the two homologs could justify the lack of proliferative capacity of human PAX4
in β-cells [34]. PAX4 also binds to the ghrelin gene promoter (at a site located in a 1.3 kb fragment
upstream of the transcription start site (TSS)) directly repressing transcription [65]. Remarkably, PAX6
has no effect on ghrelin expression, excluding competition between PAX4 and PAX6 for the same
site as the underlying mechanism. Interestingly the lack of PAX4 during embryonic development
despite not affecting single hormone ghrelin+ ε-cell population does induce the ectopic activation of
ghrelin in glucagon+ α-cells [65]. PAX4 also binds to a region in the human insulin gene promoter
(between −229 and−258) that contains a C2 and E2 site, mediating transcriptional repression [62].
Interestingly, an independent study analyzing the effect of PAX4 on the C2 element revealed that while
in α-cell lines PAX4 causes a sharp decrease in transcriptional activation, in β-cell lines it has little effect,
indicating some degree of cell-type specificity [44]. PAX4 dependent decrease of insulin expression
was also observed after in vivo overexpression of PAX4 in β-cells [37]. Interestingly, the ectopic
expression of mutant PAX4R129W that has impaired DNA binding [33,56], also decreases insulin
expression. This suggests the involvement of a PAX4 DNA-binding independent mechanism in this
genetic regulation. There are no reports regarding PAX4 role onto somatostatin expression, however
PAX6 stimulated somatostatin expression through binding to an upstream enhancer [66]. We could
also expect a PAX4–PAX6 interaction, resulting in repression of somatostatin gene transcription by
PAX4. Therefore, PAX4 is a key repressor of islet hormone genes. The inhibition of glucagon or ghrelin
by PAX4 will ensure the formation of single-hormone expressing cells. This is consistent with the
exclusion of PAX4 from α-cells to ensure glucagon expression. This exclusion process is mediated
through ARX (aristaless related homeobox) that triggers α-cell formation. ARX and PAX4 inhibit each
other expression through binding to specific DNA sites. PAX4 binds to a conserved enhancer region
in Arx, located 14.2 kb downstream of the translation stop site, inhibiting Arx transcription. On the
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other hand, ARX binds to Pax4 in a conserved pancreatic enhancer region inhibiting Pax4 expression.
This mutual inhibition ensures proper endocrine fate [24].
PAX4-dependent inhibition of insulin promoter paradoxically suggests that high PAX4 expression
maintains β-cells in an immature status. In agreement with this, PAX4 can also inhibit the expression of
several mature β-cell markers. PAX4 binds to and represses the promoter of islet amyloid polypeptide
(IAPP or amylin), which is co-secreted with insulin [62]. MAFA, an important factor during the
acquisition of glucose responsiveness in neonatal β-cells [67], is inhibited by ectopic expression of
PAX4 in β-cells in vivo [37]. This action is mediated, at least in part, through the conserved R3 region
of MafA located 8 kb upstream of the TSS [37,68]. Interestingly, PAX4 mutant variant PAX4R129W has
a similar inhibitory effect, suggesting a DNA-binding-independent action of PAX4. Since PAX6 also
binds to the R3 region [69] activating MafA transcription, PAX4–PAX6 direct protein–protein interaction
might be, at least in part, mediating this negative action of PAX4 [37]. The expression of the glucose
transporter 2 (GLUT2, also termed SLC2A2) is also downregulated by PAX4 overexpression in vivo [37].
Similar to MafA and insulin regulation, mutant PAX4R129W can also inhibit the expression of Glut2.
It is tempting to speculate that in PAX4 dependent regulation of β-cell maturation a DNA-binding
independent action of PAX4 has a prominent role, however further studies to identify PAX4 interaction
partners are required to validate this hypothesis.
The existence in adult islets of a subpopulation of insulin-expressing β-cells that specifically
express PAX4 [21], suggests that PAX4 expression above a specific threshold is required for inhibition
of these mature β-cell markers. In support of this hypothesis, only after long term ectopic expression
of PAX4 in β-cells in vivo emerges a proliferative PDX1+/insulin− cell population, indicative of
the dedifferentiation of the β-cells [37]. Thus, PAX4 expression induces dedifferentiation of β-cells
allowing their proliferation. One of the downstream targets that can account for PAX4 dependent
activation of β-cell proliferation is c-Myc. Ectopic expression of mouse PAX4 in human or rat adult
islets in culture induces c-Myc expression correlating with β-cell proliferation [33,35]. Moreover,
long-term in vivo ectopic expression of PAX4 increases c-Myc and Cdk4 mRNA levels, correlating with
the increase in proliferation of PDX1+/insulin− β-cells [37]. Remarkably, transcriptome analysis of
islet cells after PAX4 overexpression in vivo revealed the downregulation of cyclin-dependent kinase
inhibitor 2A, which strongly inhibits Cdk4, [39]. Further analysis or these microarray data revealed
a functional enrichment in cell cycle pathway after PAX4 overexpression. In silico analysis of this
pathway indicated that overexpression of PAX4 increases the expression of both cell cycle activators
and cell cycle inhibitors, suggesting that PAX4 defines a proliferation permissive β-cell subpopulation
primed to expansion only under conditions that alleviate cell cycle breaks [21].
PAX4 is also a survival factor for β-cells. Several members of the intrinsic apoptotic pathway
are modulated after increased PAX4 expression. The expression of the anti-apoptotic factor Bcl-xL is
increased after overexpression of PAX4 in an insulinoma cell line as well as in isolated rat islets [34,38].
In addition, the treatment of MIN6 mouse insulinoma cell line with recombinant PAX4 protein protects
these cells from TNF-α induced apoptosis, with a concomitant increase in Bcl-xL expression [35].
In contrast, silencing of PAX4 expression in INS-1E insulinoma cell line decreases the expression levels
of Bcl-xL correlating with increased spontaneous apoptosis and higher sensitivity to cytokines-induced
apoptosis [38]. Additionally, an association between increased PAX4 expression and increased BCL-2
levels, another anti-apoptotic factor of the intrinsic pathway, has been reported in neonatal rat islets
after treatment with ciliary neurotrophic factor (CNTF) that promotes β-cell survival [36]. Ectopic
expression of PAX4 in mouse islet β-cells also correlates with an increase in Bcl-2 expression and
abrogated cytochrome C release after cytokines treatment, demonstrating the important role of PAX4
on the intrinsic apoptotic pathway. Remarkably, PAX4R129W overexpression does not increase
Bcl-2 or protect mouse islet β-cells from cytokines-induced apoptosis [37]. Supporting this, in vivo
overexpression of PAX4 renders mouse β-cells more resistant to STZ induced apoptosis, while
PAX4R129W confers only a partial protection [37]. The impairment of DNA binding of the mutant
variant and its failure in apoptosis protection suggest that PAX4 dependent regulation of the intrinsic
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apoptotic pathway requires PAX4 binding to its specific DNA sites. Reinforcing this hypothesis,
the increase in Bcl-xL expression in rat islets is more pronounced after ectopic expression of mouse
PAX4 as compared to human PAX4 that has a less efficient binding to the G3 element of the glucagon
promoter [34]. In addition to Bcl-2 and Bcl-xL, other genes involved in cell survival are upregulated by
PAX4, but not by PAX4R129W.
Transcriptome profiling on islets overexpressing PAX4 in β-cells in vivo revealed a functional
enrichment of protein processing in endoplasmic reticulum pathway, not enriched in PAX4R129W
overexpressing islets [39]. PAX4 role in the endoplasmic reticulum (ER) response was demonstrated
after treatment of isolated islets with thapsigargin, an inhibitor of ER Ca2+-ATPases, which induces
ER-stress dependent apoptosis. PAX4 overexpressing islets showed preservation of ER integrity
and decreased apoptosis after thapsigargin treatment. This protection was lost when PAX4R129W
mutant was overexpressed [39]. Silencing of endogenous PAX4 in MIN6 sensitized cells to
thapsigargin-induced apoptosis, clearly demonstrating the importance of PAX4 in maintaining ER
homeostasis [39]. In this context, PAX4 increased expression of calreticulin (CALR), a Ca2+ binding
protein involved in ER homeostasis whereas PAX4R129W decreased its transcript levels. PAX4 was
also recently shown to protect β-cells against apoptosis in an experimental model of autoimmune
diabetes correlating with a significant decrease in islet immune cells infiltration (insulitis), suggesting
the involvement of this transcription factor in immune modulation. Although the mechanism remains
to be defined, a potential target implicated in this process that was increased by PAX4 but not
PAX4R129W is Galectin 9 (LGALS9) [39]. LGALS9 is known to have potent immunomodulatory
functions, capable of reducing insulitis and hyperglycemia in Non Obese Diabetic (NOD) mice [70,71],
as well as prolonging islet grafts survival [72]. A PAX4-dependent increase in Lgals9 expression
might be one of the mechanisms implicated in PAX4 immunomodulatory action. In PAX4-mediated
regulation of these pro-survival genes, the PD of the transcription factor has a major role, since the
PAX4R129W mutant fails to activate their expression. Therefore, we can hypothesize that PAX4
dependent binding to DNA is required for this regulation. Whether it is a direct regulation or
intermediate factors are required remains to be determined.
5. PAX4 Regulation
In adult mouse islets, PAX4 expression is restricted to a subpopulation of β-cells that are prone
to proliferation and more resistant to apoptosis. The relative abundance of this subpopulation of
PAX4+β-cells increases under physiological situations that require an increase in the proliferation
of β-cells such as pregnancy [21] indicating a stringent regulation of this factor even within a single
cell phenotype.
5.1. Epigenetic Regulation of PAX4
Several epigenetic modifications have been shown to control Pax4 expression. Treatment of
rat islets with a DNA-methyltransferase inhibitor, 5′AZA, stimulates endogenous Pax4 expression
and consequently expression of its downstream target Bcl-xL, suggesting that demethylation of Pax4
promoter is an epigenetic modification controlling Pax4 expression [34]. Moreover, demethylation of
the human PAX4 promoter region located−1347 to−1103 bp from translation initiation site (Figure 2A)
has been linked to aberrant expression of PAX4 in lymph nodes of patients with diffuse large B cell
lymphoma (DLBCL) as well as in several hematological cell lines [73]. Of note, hematological organs
do not express PAX4 under physiological conditions. In agreement with this, treatment of lymphocyte
cell lines devoid of PAX4 expression with 5′AZA robustly induces expression of PAX4. In addition,
treatment of pancreatic explants with MG1568, an inhibitor of class IIa histone deacetylases (HDACs)
enhanced the expression of Pax4 [74]. This activation was transient reaching a peak of expression
between days 5 and 9 in culture reverting to basal levels by day 11. Noteworthy, by day 11, insulin and
MafA expression were significantly increased in MG1568-treated explants [74]. These findings suggest
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that Pax4 activation promotes dedifferentiation and expansion but that repression is mandatory to
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Figure 2. Mouse Pax4 gene and regulatory upstream region. (A) Schematic structure of mouse
Pax4 (top) and human PAX4 (bottom) loci according to UCSC Genome Browser annotations
(http://genome.ucsc.edu/). Exons are depicted as grey squares. Transcription start site (TSS) is
indicated by an arrow. In human PAX4 two different TSS have been defined: TSS pl: placental TSS and
TSS p: pancreatic TSS. Triangle represents first codon. Green box represents the promoter region that
directs pancreatic expression of PAX4. Yellow box indicates the localization of the neuron-restrictive
silencer element (NRSE). Red box represents the localization of the PAX4 binding sites in human
promoter. Cyan box represents the demethylated region in hematologic malignancies. (B) Alignment
of human and mous 0.4 kb promoter region that direc s pancreatic expression of PAX4. In dark
green is indicated the 0.1 kb region identifie in human. Boxes indicate the location of the potential
transcription factors binding sites. (C) Alignment of human and mouse NRSE.
5.2. Genetic Regulation of PAX4
Studies aiming at the characterization of PAX4 functional promoter identified a highly conserved
(88% sequence homology between mouse and human) 0.4 kb fragment located 2 kb upstream of the
mouse Pax4 TSS (Figure 2) that is sufficient for driving Pax4 expression in pancreas in vivo[75,76].
This region is hypomethylated in β- and non-β-cells of adult mouse islets [21]. In an independent study,
a 0.1 kb region located 2 kb upstream of human PAX4 TSS was found to be both necessary and sufficient
to drive pancreas specific expression of PAX4 [77]. This human pancreas specific promoter element is
located within the highly conserved 0.4 kb fragment identified in mice (Figure 2B), highlighting the
importance of this region for PAX4 regulation in pancreas. Hepatocyte nuclear factor 4 alpha (HNF4α),
HNF1 homeobox A (HNF1α), PDX1, and neuronal differentiation 1 (NEUROD1) / neurogenin 3
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(NEUROG3) were shown to interact within this region [77] (Figure 2B). Interestingly, among these
five putative regulators of PAX4, four of them are established Maturity-Onset Diabetes of the Young
(MODY) genes: HNF4α-MODY1, HNF1α-MODY3, PDX1-MODY4 and NEUROD1-MODY6. Further
functional studies in non-β cells showed that a combination of these factors, HNF4α, HNF1α, PDX1 and
NEUROD1, together with PAN1 increased expression of a reporter construct harboring this promoter
region while alone they had no impact. Substituting NEUROD1 by NEUROG3 further increased
activation indicating that these factors are likely involved in the regulation of PAX4 during pancreas
organogenesis [77]. Further analysis of these sites in a β-cell line revealed that mutation in either the
HNF1α or NEUROD1/NEUROG3 binding site caused a strong decrease in the promoter activity, while
mutation of HNF4α site had a minor effect [78]. Expression of NEUROG3 and HNF1α together, but not
individually, induced endogenous PAX4 transcription in a non-pancreatic cell line. These data indicate
that PAX4 activation requires the co-expression of NEUROG3 and HNF1α [78]. In agreement with this,
ectopic expression of NEUROG3 alone in pancreatic ductal cells that express endogenous HNF1α, was
able to induce endogenous PAX4 expression [78,79]. NEUROD1, a downstream target of NEUROG3
that binds to the same site as NEUROG3 in the PAX4 promoter also induced expression of endogenous
PAX4 in pancreatic ductal cells, but not in HeLa cells. However, noteworthy is the fact that after
NEUROG3 ectopic expression in ductal cells PAX4 is increased prior to NEUROD1 stimulation [79].
In addition to these binding sites, the 5′ end fragment of the human PAX4 promoter (−4958 to −2153)
contains two additional binding sites for PAX4 (Figure 2) mediating a negative feedback loop on its
own expression [77]. Accordingly, reporter assays using the full-length 4958 bp promoter (containing
the two putative binding sites), showed that co-expression with PAX4 repressed the activity of the
promoter, and that this effect was more prominent in α-TC cells. Removal of the 5′ region containing
these putative binding sites resulted in a milder repression by PAX4.
Interestingly, 0.5 kb downstream of the pancreas specific promoter element a 21 bp cis-regulatory
motif for a neuron-restrictive silencer factor (NRSF, also termed REST) was identified (Figure 2A).
This Pax4 NRSE (neuron-restrictive silencer element) is conserved throughout evolution (Figure 2B)
and confers NRSF-dependent transcriptional repression of Pax4 [80]. Due to the fact that REST is not
expressed in neuronal cells nor in β-cells [81,82] this mechanism of repression is not expected to be
active in β-cells and will probably be involved in regulation of the specific pattern of expression
of PAX4. Moreover, high mobility group 20A (HMG20A, also known as IBRAF), a chromatin
remodeling factor implicated in the relief of transcriptional repression induced by the LSD1-CoREST
complex, is expressed in pancreatic islets, and mutations in this gene have been associated with
T2DM [83]. Further studies are required to establish the link between PAX4 expression and HMG20A
regulatory function.
Different treatments known to stimulate β-cell proliferation have been associated with activation
of Pax4 expression. Treatment of rodent islets with mitogens, such as activin A (belonging to TGF-β
family) or betacellulin (belonging to EGF family) increases β-cell proliferation concomitantly with
the induction of Pax4 expression [33]. Inhibition of the PI3-kinase pathway by betacellulin abrogates
induction of Pax4 expression and subsequent β-cell proliferation, revealing the implication of this
pathway in the activation of Pax4 expression. Moreover, the treatment of pancreatic explants with
betacellulin promotes β-cell fate at the expense of α-cell destiny [84]. In contrast, TGF-β1, another
member of the TGF-β family, does not have a significant effect on Pax4 mRNA levels, or on islet cell
proliferation [13,33]. In addition, Pax4 expression in human islets is also increased under high glucose
concentration in vitro. Most likely insulin released in response to high glucose is the main stimulator
of Pax4 transcription, as blocking insulin secretion inhibits the increase in Pax4 mRNA, while insulin
treatment mimics the effect of high glucose [18]. Interestingly further increase in glucose concentration
(33 mM) caused Pax4 repression, probably due to high levels of IL-1β [18]. It is tempting to speculate
that during the initial stages of T2DM the increase in blood glucose may have a stimulatory action
on Pax4 expression, favoring the proliferation of β-cells detected in these patients. Further increase
in glucose levels or maybe longer time in the presence of high blood glucose, could be mediating
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opposite effect by increasing IL-1β and therefore inhibiting Pax4 expression contributing to β-cell
death observed during later stages of the disease. Strengthening the possible involvement of high
glucose levels on PAX4 expression, endogenous PAX4 mRNA levels are increased in T2DM donors
with body mass index (BMI) between 22 and 26. Higher BMI donors have lower expression levels of
PAX4 indicating that long term exposure and lipotoxicity suppresses PAX4 expression [18].
5.3. Posttranslational Regulation of PAX4
In addition to genetic and epigenetic regulation, posttranslational modifications (PTMs) are
likely involved in modulating PAX4 activity, yet little is known. One such PTMs is SUMOylation
that regulates transcription factors function by fine-tuning the activity of the factor by modulating
protein stability, cellular localization, DNA binding and interaction with partners [85–90]. As such
SUMOylation was shown to regulate the activity of key β-cell proteins such as MAFA, PDX1 and
Glukokinase [91]. Of particular interest, SUMO-4 was identified as a candidate gene implicated in
Type 1 diabetes susceptibility [92]. Furthermore, increased SUMOylation as well as overexpression of
SUMO1 protects INS-1 cells against IL-1β induced apoptosis. In contrast, ectopic expression of the
deSUMOylating enzyme SENP1 sensitizes this cell line to apoptosis induced by IL-1β [93]. These effects
are reminiscent of either PAX4 overexpression protecting against cytokine-induced apoptosis or its
repression sensitizing to apoptosis. Interestingly, SUMOylation regulates the transcriptional activity
of PAX6, by modulating the binding activity (Yan, et al. 2010). The SUMOylation site within PAX6 is
conserved in PAX4 suggesting the potential SUMOylation of PAX4.
In silico analysis of PAX4 revealed the presence of several additional putative SUMOylation sites
conserved in human and mouse PAX4 proteins (Figure 3). Two SUMOylation consensus sites (ψKXE
where ψ is a hydrophobic residue and X is any amino acid) with the SUMO acceptor Lys at position 92
and 232 were predicted. Moreover, adjacent to the 232-site a second Lys that could also be SUMOylated
was identified in both proteins. These analyses prompt us to investigate whether human and mouse
PAX4 were SUMOylation targets. Our studies show that both human and mouse PAX4 proteins are
SUMOylated by SUMO1 and SUMO2 in the presence of the SUMO conjugating enzyme Ubc9 and
without the requirement of any of the protein inhibitor of activated STAT (PIAS) SUMO E3 ligases
(Figure 3). This opens a new regulatory level of PAX4 activity. Mutational analysis of the putative
SUMO acceptor Lys will determine the main site for SUMOylation for PAX4 and reveal whether this
PTM can modify the transcription regulation potential of PAX4.
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Figure 3. Mouse and human PAX4 proteins are SUMOylated. (A) Alignment of mouse PAX4 (PAX4 (m)
UniProtKB P32115) and human PAX4 (PAX4 (h) UniProtKB O43316) protein sequences using Clustal
Omega. PD is indicated in purple and HD in blue. The predicted SUMOylation sites are indicated
by grey squares. (B) Western blot of cellular extracts from 293T cells transfected with Myc-tagged
mouse Pax4 (left panels) or a PAX4 (right panels) alone or in combination with SUMO2 and
Ubc9. Co-tr nsfection of PAX4 w th SUMO2 a Ubc9 resu ts in t e det ct on of ylated PAX4.
α-Tubulin was used as loading control (l wer panels). Interestingly, human PAX4 SUMOylation is
stronger when compared with mouse PAX4. In both cases, the co-expression of SUMO2 and Ubc9 seems
to increase the stability of PAX4 protein, as indicated by the stronger band for unSUMOylated PAX4.
(C) Western blot analysis of 293T cells transfected with Flag-tagged PAX4 alone or in combination
with Ubc9, SUMO1 or SUMO2, shows human PAX4 SUMOylation by both SUMO1 and SUMO2 only
when Ubc9 is co-expressed. (D) Analysis of extracts of 293T cells untransfected or transfected with
Myc-tagged PAX4 alone or in combination with His-Tagged SUMO2 and Ubc9, using anti-Myc (left
panel) or anti-His (right panel) antibodies, revealed the specificity of the SUMOylated bands. The lower
band ~20 kD in the a ti-His blot corresponds to free SUMO. (E) Pull down using His-Trap matrix of
extracts from 293T cells transfected with Ha-tagged PAX4 alone or i combination with His-tagged
SUMO2 and Ubc9 showing the specific pull down of SUMOylated PAX4, indicated by arrows.
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6. Conclusions
PAX4 is a key factor regulating β-cell survival and proliferation in adult islet β-cells, therefore
an interesting target for the development of novel therapies for DM treatment aimed at sustaining
a functional β-cell mass. The activation of endogenous Pax4 expression is an adaptive response
intrinsic of the β-cells as revealed by the described correlation between the abundance of the PAX4+
β-cell population and the proliferative capacity of the islets [21]. Moreover, the increase in Pax4
expression in mice treated with STZ [94], together with the higher resistance of PAX4+ β-cells to STZ
induced apoptosis [21] indicates that Pax4 stimulation is also a mechanism of protection inherent of
the β-cells. Therefore, stimulating agents that activate this β-cell response could be used for enhancing
proliferation and resistance to apoptosis in β-cells. However, long term high expression of PAX4
can induce dedifferentiation of the β-cells causing islets dysfunction. Therefore, wide knowledge
on the genetics of PAX4 mechanism of action is needed, to be able to potentiate PAX4 protection
against cell death without causing the detrimental dedifferentiation of the β-cells. In this regard,
the comparative functional analysis of PAX4 and a mutant variant associated with DM, R129W, has
revealed the existence of, at least, two different mechanism of action for this transcription factor [37,39]
(Figure 4). On one the hand, PAX4 acts as a survival factor for β-cells, regulating different anti-apoptotic
members of the Bcl2 family as well as preserving ER homeostasis, through a mechanism that requires
an intact PD, since PAX4R129W (mutation located in the PD) does not regulate these genes/pathways.
As a result of R129W mutant PAX4 has impaired DNA binding, therefore this pro-survival action of
PAX4 is mediated through binding to consensus response elements in PAX4 target genes. On the other
hand, high PAX4 levels decrease the expression of mature β-cell markers indicating dedifferentiation of
the β-cells, and remarkably PAX4R129W has the same effect as the WT protein. Thus, this mechanism
of action of PAX4 seems to be independent of its binding to the conventional response elements.
Protein–protein interaction mechanisms, as described for PAX4–PAX6, could be mediating this effect.
Nevertheless, since the HD of PAX4R129W remains intact, binding to DNA sites specific for this
second DBD could also be involved. However, further studies are required to validate this hypothesis.
It is tempting to speculate that understanding the molecular and genetic mechanisms underlying
these different actions of PAX4 could convey in a development of a better response, by increasing
the protective actions of PAX4 without inducing β-cell dedifferentiation. This is highly relevant in
the case of diabetic patients harboring mutations in PAX4 PD. These mutations, similar to R129W,
may hamper the pro-survival action of PAX4 while retaining its β-cell dedifferentiation capacity.
Identification of PAX4 downstream targets that account for PAX4 anti-apoptotic actions may lead to the
identification of new druggable targets that will result in a more appropriate therapeutic intervention
for these individuals.
The finding that PAX4 is SUMOylated opens a new level of regulation of its activity. In silico
analysis of PAX4 indicates that at least four Lys conserved between human and mouse PAX4 could be
SUMOylated. SUMOylation of transcription factors has been frequently associated with a decrease in
their transcriptional activity, due to the sequestering of the factors in nuclear bodies or inactivation
of their TADs. However, in the case of PAX6, K91 SUMOylation in p32 PAX6 (isoform of PAX6 that
lacks the PD) activates the DNA binding of the HD, thus stimulating the transcriptional activity of this
isoform (Yan, et al. 2010). This site is conserved in PAX4 (K187 in mouse PAX4) and could thus also be
involved in modulating PAX4 HD binding activity. Similarly, the SUMO site located in PAX4 PD (K92 in
mPax4) could be involved in the modulation of the binding to specific sites for this DBD. Interestingly
the third and fourth putative SUMOylation sites (K230 and K232 in mouse PAX4) are located in the
C-terminal region of PAX4, which contains a TAD and a repressor domain. SUMOylation close to
these types of domains have been shown to decrease their activity [89], and could be a mechanism
of regulation of PAX4 activity. However, mutational analyses to identify the SUMO acceptor Lys to
characterize the functional consequence of this PTM are necessary.
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sustain  the possible  future use of PAX4  in  regenerative  therapies.  In addition,  stimulation of  the 
expression/activity of this transcription factor could also be beneficial in islets transplantation for DM 
treatment.  In vitro  treatment of  isolated  islets  to stimulate PAX4 expression/activity prior  to  their 
transplant could result in increased survival of the grafts and thus improved outcome for the patient. 
Figure 4. PAX4 mechanism of action. The differences observed in the regulation mediated by PAX4
WT and the diabetes linked mutant PAX4R129W has revealed the existence of, at least, two different
mechanisms of action for PAX4. The main DBD of PAX4, the PD, is required for the upregulation
of genes and pathways implicated in the increased survival of β-cells, while the dedifferentiation of
β-cells seems to be independent of this DBD. R129W mutation and predicted SUMOylation sites (S)
are indicated in the schematic representation of mouse PAX4 (PAX4 (m)) protein. PD is indicated in
purple, HD in blue. Green box indicates the region where the TAD is located and red box the region
including the repressor domain.
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4 [25,41,42] opens ew possibilities towards the development f novel gene therap utic approaches
to treat DM. This mechanism will not only provide an alternative to i crease β-cell mass, but al o
maintaining an α to β cell ratio, important f dequate gl cose homeostasis. Moreover, the proof
of c ncept in mouse mod ls that in r -bile ductal injectio of adenoviruses expressing human PAX4
provided therapeutic b nefits [41,42] points at the use of PAX4 in gene therapy.
capacity of functional PAX4 protein to enter into living cells opens a new venue of PAX4 itself
as a ther peutic tool. Different studies have focus d n the use of PTDs and cell penetrating peptides
(CCPs) for the delivery of therapeutic proteins n the reatment of diseas s [95]. Ther fore, PAX4 innate
capacity to ransduce into living cells maintaining its func io ality i advantageous. Underst nding
PAX4 mechanisms of action s well as the fu ctiona effect of SUMOylation on this transcription factor
could encourage he generation of gene ically modified PAX4 proteins with reduced dediffere tiation
potential an inc ased protec ive ctions that can be used as therapeutic proteins. However, due to the
unspecific cell penetration of PAX4, adequate delivery plat orms nee to be developed. Additio ally,
further analyses of the penetration efficiency of PAX4 are necessary to determine the appli abilit
of this approach. Neverthe ess, it is an a pe ling strategy to modify the expression/action of PAX4
without genetic manipulation.
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.









early post‐natal  life. During adulthood,  increases  in the  insulin demand  induce Pax4 expression to 





Progreso  y  Salud,  Junta  de  Andalucía  (PI‐0727‐2010  to  B.R.G.  and  PI‐0085‐2013  to  P.I.L.),  Consejería  de 
Economía, Innovación y Ciencia, Junta de Andalucía (P10‐CTS‐6359 to B.R.G. and P12‐CTS‐2064 to M.G.‐D.), 
Figure 5. PAX4 regulation and action during development and adulthood. During embryonic
development, NEUROG3, HNF1α and probably HNF4α activate PAX4 expression in progenitor
cells inducing their commitment towards β-cells through inhibition of other islet cell master factors
(ARX and islet hormone genes). Later on during development, PAX4 expression is tune down to allow
full expression of β-cell markers (MAFA, GLUT2, insulin) conferring full functionality to β-cells during
early post-natal life. During adulthood, increases in the insulin demand induce Pax4 expression to
confer a more plastic behavior of the β-cells (increase in apoptosis resistance and prone to proliferation)
that allows the adaptation of the islets to the new metabolic demands. However, if Pax4 stimulation is
maintained for long term, it can cause the dedifferentiation of the β-cells (decrease in mature β-cell
markers), with subsequ nt inability to r gulat glucose homeostasis.
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